Oxybutynin Tablet, Film Coated, Extended Release
Product Images NDC 0615-8219

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Oxybutynin (NDC 0615-8219). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ncs Healthcare Of Ky, Llc Dba Vangard Labs, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Oxybutynin Chloride Extended-release Tablet (Oxybutynin Chloride Er Tabs 5mg 10mg Zyduscadila 1)

Chemical structure of oxybutynin hydrochloride, illustrating the molecular arrangement including phenyl, cyclohexyl, and ethyl groups with the hydrochloride ion.*

FDA Label Image

Oxybutynin Chloride Extended Release Tablets (Oxybutynin Chloride Er Tabs 5mg 10mg Zyduscadila 2)

A pharmacokinetic line graph showing the mean plasma concentration (ng/mL) of oxybutynin over 24 hours. It compares oxybutynin chloride extended-release tablets 10 mg once daily (QD) with oxybutynin 5 mg three times daily (TID). The x-axis represents time in hours, and the y-axis represents plasma concentration, with data points and error bars depicted.*

FDA Label Image

Oxybutynin Chloride Extended Release Tablets (Oxybutynin Chloride Er Tabs 5mg 10mg Zyduscadila 3)

A line graph showing mean R-oxybutynin plasma concentration (ng/mL) over time (hours). The graph displays data points from 0 to 24 hours with error bars indicating variability at each time point, illustrating the plasma concentration profile of the drug over one day.*

FDA Label Image

Oxybutynin Chloride Er Tablets (Oxybutynin Chloride Er Tabs 5mg 10mg Zyduscadila 4)

A chart showing the mean change in the number of urge urinary incontinence episodes per week from baseline in two studies comparing oxybutynin chloride extended release tablets versus placebo. The chart includes sample sizes, baseline means, standard deviations, and 95% confidence intervals for the difference in episodes.*

FDA Label Image

Oxybutynin Chloride Er Tablets (Oxybutynin Chloride Er Tabs 5mg 10mg Zyduscadila 5)

A data table presenting comparative mean changes in episodes per week from baseline for oxybutynin chloride extended release tablets versus placebo in a study with participant numbers and statistical measures. Accompanying plots illustrate mean changes with standard deviations for oxybutynin chloride extended release tablets and oxybutynin.*

FDA Label Image

Oxybutynin Chloride Er 5mg Tabs Bingo Card Label (Oxybutynin Chloride Er Tabs 5mg 10mg Zyduscadila 6)

Label for oxybutynin chloride extended-release tablets USP 5 mg by NCS HealthCare of KY, LLC dba Vangard Labs. The label includes dosage strength, lot number (8219), barcode, storage instructions at 20°-25°C, and directions to swallow tablets whole without chewing, dividing, or crushing. The package quantity is 30 tablets, with multiple small barcode labels for individual tablet packaging or institutional use.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.